Alibaba Health Information Technology Limited (ALBHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alibaba Health Information Technology Limited (ALBHF) with AI Score 45/100 (Weak). Alibaba Health Information Technology Limited operates a pharmaceutical e-commerce platform and provides healthcare services in Mainland China and Hong Kong. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Alibaba Health Information Technology Limited (ALBHF) Healthcare & Pipeline Overview
Alibaba Health Information Technology Limited operates a leading pharmaceutical e-commerce platform in China, offering prescription drugs, OTC medications, and healthcare services through online and offline channels, leveraging its connection to Alibaba's vast ecosystem to capture a significant share of the growing digital healthcare market.
Investment Thesis
Alibaba Health presents a compelling, albeit risky, investment opportunity within China's rapidly expanding digital healthcare market. The company's strong connection to Alibaba Group provides a significant competitive advantage, driving user acquisition and platform growth. With a P/E ratio of 31.50 and a profit margin of 5.8%, the company demonstrates profitability, but investors should be aware of the high beta of 1.72, indicating higher volatility compared to the market. Growth catalysts include the increasing adoption of online pharmacies and digital healthcare services in China, driven by convenience and accessibility. Key risks involve regulatory uncertainties in the Chinese healthcare sector and competition from other established players. The company's ability to maintain and expand its market share, while navigating the complex regulatory landscape, will be crucial to its long-term success.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $10.61 billion reflects significant investor interest in the company's growth potential.
- P/E ratio of 31.50 indicates a premium valuation, suggesting high expectations for future earnings growth.
- Profit margin of 5.8% demonstrates profitability in a competitive market.
- Gross margin of 24.5% reflects the company's ability to manage costs effectively.
- Beta of 1.72 indicates higher volatility compared to the market, suggesting a riskier investment profile.
Competitors & Peers
Strengths
- Strong brand recognition and reputation
- Established e-commerce platform and logistics network
- Relationship with Alibaba Group
- Extensive product and service offerings
Weaknesses
- Reliance on Alibaba Group
- Exposure to regulatory risks in China
- Intense competition in the digital healthcare market
- OTC listing may limit investor access
Catalysts
- Ongoing: Expansion of online pharmacy business driven by increasing internet penetration in China.
- Ongoing: Growth in telemedicine and digital health services due to rising healthcare costs and demand for remote care.
- Upcoming: Potential regulatory approvals for new pharmaceutical products or healthcare services.
- Upcoming: Strategic partnerships or acquisitions to expand product offerings and market reach.
- Ongoing: Increasing demand for healthcare services in lower-tier cities and rural areas.
Risks
- Ongoing: Regulatory changes in China's healthcare sector could impact the company's operations and profitability.
- Ongoing: Intense competition from other players in the digital healthcare market.
- Potential: Economic slowdown in China could reduce consumer spending on healthcare products and services.
- Potential: Cybersecurity risks could compromise the company's data and systems.
- Ongoing: Reliance on Alibaba Group exposes the company to risks associated with its parent company's business and reputation.
Growth Opportunities
- Expansion of Online Pharmacy Business: The increasing adoption of online pharmacies in China presents a significant growth opportunity for Alibaba Health. The market for online pharmacies is projected to reach billions of dollars in the coming years, driven by convenience and accessibility. Alibaba Health can leverage its existing e-commerce platform and logistics network to capture a larger share of this market. The timeline for this growth is ongoing, with continuous expansion expected over the next 3-5 years.
- Growth in Telemedicine and Digital Health Services: The demand for telemedicine and digital health services is growing rapidly in China, driven by factors such as increasing healthcare costs and a shortage of healthcare professionals. Alibaba Health can capitalize on this trend by expanding its telemedicine offerings and developing new digital health services, such as remote monitoring and chronic disease management. This growth is expected to accelerate over the next 2-3 years.
- Penetration into Lower-Tier Cities and Rural Areas: While Alibaba Health has a strong presence in major cities in China, there is significant potential to expand into lower-tier cities and rural areas. These areas have a large population and increasing demand for healthcare services. Alibaba Health can leverage its e-commerce platform and logistics network to reach these underserved markets. Expansion into these regions is expected to unfold over the next 3-5 years.
- Development of New Healthcare Products and Services: Alibaba Health can drive growth by developing new healthcare products and services that cater to the evolving needs of its customers. This could include developing new over-the-counter medications, nutritional supplements, and medical devices. It could also involve offering new healthcare services, such as personalized medicine and genetic testing. New product and service development is an ongoing process.
- Strategic Partnerships and Acquisitions: Alibaba Health can accelerate its growth through strategic partnerships and acquisitions. This could involve partnering with other healthcare companies to expand its product and service offerings or acquiring companies with complementary technologies or market access. Strategic partnerships and acquisitions are expected to occur opportunistically over the next few years.
Opportunities
- Expansion of online pharmacy business
- Growth in telemedicine and digital health services
- Penetration into lower-tier cities and rural areas
- Development of new healthcare products and services
Threats
- Regulatory changes in China
- Increased competition from other players
- Economic slowdown in China
- Cybersecurity risks
Competitive Advantages
- Strong brand recognition and reputation.
- Established e-commerce platform and logistics network.
- Relationship with Alibaba Group provides access to a large user base and technology infrastructure.
- Extensive product and service offerings.
About ALBHF
Alibaba Health Information Technology Limited, formerly known as CITIC 21CN Company Limited, rebranded in September 2014 following its acquisition by Alibaba Group. The company has evolved into a comprehensive healthcare platform, operating primarily in Mainland China and Hong Kong. Its core business revolves around pharmaceutical direct sales and its pharmaceutical e-commerce platform. Through online stores on Tmall.com and offline pharmacy outlets, Alibaba Health provides a wide array of products, including prescription drugs, over-the-counter medications, nutritional supplements, and medical devices, catering to both business-to-customer (B2C) and business-to-business (B2B) segments. The company's e-commerce platform extends its offerings to include health food, sexual health products, contact lenses, and various medical and healthcare services. Alibaba Health also provides medical and healthcare services, such as medical checkups, nucleic acid testing, medical consultation, registration, vaccination, and Traditional Chinese Medicine (TCM) consultations through multiple channels like Taobao, Tmall, Alipay, Dr. Deer APP, Gaode, DingTalk, and Quark. Beyond its core e-commerce activities, Alibaba Health engages in tracking services, operates network hospitals, and provides healthcare-related internet information and technical services.
What They Do
- Operates an online pharmaceutical e-commerce platform.
- Sells prescription drugs, over-the-counter medications, and health-related products.
- Provides medical and healthcare services, including medical checkups and consultations.
- Offers telemedicine and digital health services.
- Operates network hospitals.
- Provides healthcare-related internet information and technical services.
Business Model
- Generates revenue from the sale of pharmaceutical products and healthcare services.
- Operates an e-commerce platform, connecting customers with healthcare providers and products.
- Leverages its relationship with Alibaba Group to drive user acquisition and platform growth.
Industry Context
Alibaba Health operates within China's rapidly growing digital healthcare market. The industry is characterized by increasing adoption of online pharmacies, telemedicine, and digital health services, driven by factors such as increasing internet penetration, rising healthcare costs, and government support for digital health initiatives. The competitive landscape includes traditional pharmaceutical companies, online pharmacies, and technology companies entering the healthcare space. Alibaba Health benefits from its association with Alibaba Group, giving it a strong competitive advantage in terms of brand recognition, technology infrastructure, and user base.
Key Customers
- Individual consumers seeking pharmaceutical products and healthcare services.
- Businesses purchasing pharmaceutical products for resale or use in their operations.
- Healthcare providers seeking to expand their reach and offer digital health services.
Financials
Chart & Info
Alibaba Health Information Technology Limited (ALBHF) stock price: Price data unavailable
Latest News
-
Alibaba Health Information Technology (OTC:ALBHF) Shares Down 6.4% – What’s Next?
defenseworld.net · Feb 24, 2026
-
Stocks That Managed to Breach 52-Week Lows Friday
· Jul 26, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALBHF.
Price Targets
Wall Street price target analysis for ALBHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALBHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Difan Shen
CEO
Difan Shen serves as the CEO of Alibaba Health Information Technology Limited, overseeing the company's strategic direction and operations. His background likely includes extensive experience in the technology and healthcare sectors, though specific details are not provided in the source data. He is responsible for managing a workforce of 1422 employees and driving the company's growth in the competitive digital healthcare market. Further information on his educational background and previous roles is unavailable.
Track Record: Information on Difan Shen's specific achievements and strategic decisions as CEO of Alibaba Health is not available in the provided source data. Therefore, a detailed assessment of his track record cannot be provided. His leadership is crucial to the company's ability to navigate the complex regulatory landscape and capitalize on growth opportunities in the Chinese healthcare market.
ALBHF OTC Market Information
The OTC Other tier, where ALBHF trades, represents the lowest tier of the OTC market. Companies in this tier often have limited financial disclosure and may not meet the minimum listing requirements of exchanges like the NYSE or NASDAQ. This tier is characterized by higher risk and less regulatory oversight compared to higher-tier OTCQX and OTCQB markets. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier, as information availability may be limited and the potential for fraud or manipulation is higher.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry and the risk of making uninformed investment decisions.
- Lower trading volume and wider bid-ask spreads can lead to price volatility and difficulty in executing trades.
- The OTC Other tier has less regulatory oversight, increasing the potential for fraud or manipulation.
- OTC stocks may be more susceptible to pump-and-dump schemes.
- Delisting from the OTC market could result in significant losses for investors.
- Verify the company's registration and legal standing.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings involving the company.
- Association with Alibaba Group provides a degree of credibility.
- Operating in the regulated healthcare industry suggests some level of oversight.
- Presence on the OTC market indicates the company is publicly traded.
- Company has been in operation since before 2014.
- Company has over 1400 employees.
Alibaba Health Information Technology Limited Stock: Key Questions Answered
What does Alibaba Health Information Technology Limited do?
Alibaba Health Information Technology Limited operates as a key player in China's digital healthcare landscape. It primarily focuses on running a comprehensive pharmaceutical e-commerce platform, offering a wide range of prescription and over-the-counter drugs, along with various health-related products. Beyond its e-commerce activities, the company provides diverse medical and healthcare services, including online medical consultations, health checkups, and access to traditional Chinese medicine. By leveraging its connection to Alibaba's vast ecosystem, Alibaba Health aims to provide convenient and accessible healthcare solutions to a large customer base.
What do analysts say about ALBHF stock?
Due to the limited information available, a comprehensive analyst consensus on ALBHF stock cannot be provided. However, considering its position in the growing Chinese digital healthcare market and its association with Alibaba Group, analysts likely view the company as having significant growth potential. Key valuation metrics, such as the P/E ratio of 31.50, suggest that investors have high expectations for future earnings. However, the high beta of 1.72 also indicates a higher level of risk compared to the overall market. Investors should conduct their own thorough research and consider their risk tolerance before investing in ALBHF.
What are the main risks for ALBHF?
Alibaba Health faces several key risks. The regulatory environment in China's healthcare sector is subject to change, which could impact the company's operations and profitability. Intense competition from other players in the digital healthcare market poses a threat to its market share. An economic slowdown in China could reduce consumer spending on healthcare products and services. Cybersecurity risks could compromise the company's data and systems. Finally, the company's reliance on Alibaba Group exposes it to risks associated with its parent company's business and reputation. These risks should be carefully considered by potential investors.
What are the key factors to evaluate for ALBHF?
Alibaba Health Information Technology Limited (ALBHF) currently holds an AI score of 45/100, indicating low score. Key strength: Strong brand recognition and reputation. Primary risk to monitor: Ongoing: Regulatory changes in China's healthcare sector could impact the company's operations and profitability.. This is not financial advice.
How frequently does ALBHF data refresh on this page?
ALBHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALBHF's recent stock price performance?
Recent price movement in Alibaba Health Information Technology Limited (ALBHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong brand recognition and reputation. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALBHF overvalued or undervalued right now?
Determining whether Alibaba Health Information Technology Limited (ALBHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALBHF?
Before investing in Alibaba Health Information Technology Limited (ALBHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-traded companies.
- Analyst consensus data not available.
- CEO track record details not available.